Overview Dividends

(VRDN) Viridian Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92790C1045

Monoclonal Antibody, Thyroid Eye Disease, Autoimmune Disease, Clinical Trial

Biotechnology
Market Cap in USD: 3,016m

IPO / Inception: 2014-06-18
Return 12m vs S&P 500: 41.7%

EPS (Earnings per Share)

EPS CAGR: 39.53%
EPS Trend: 52.2%

Last SUE: 2.68
Qual. Beats: 1

Revenue

Rev. CAGR: 369.38%
Rev. Trend: 12.2%

Last SUE: 4.00
Qual. Beats: 1

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	60.1%
Value at Risk 5%th	92.4%
Relative Tail Risk	-6.47%

Reward TTM
Sharpe Ratio	1.23
Alpha	54.31
CAGR/Max DD	0.06

Character TTM
Hurst Exponent	0.392
Beta	0.905
Beta Downside	0.714

Drawdowns 3y
Max DD	70.69%
Mean DD	46.65%
Median DD	50.16%

Description: VRDN Viridian Therapeutics November 12, 2025

Viridian Therapeutics (NASDAQ: VRDN) is a U.S. biotech focused on monoclonal-antibody therapies for rare and serious diseases, most notably thyroid eye disease (TED). The firm originated as Miragen Therapeutics and rebranded in January 2021; it is headquartered in Waltham, Massachusetts and trades as a common-stock biotech under the GICS sub-industry “Biotechnology.”

The current pipeline centers on two IGF-1R-targeting antibodies in Phase 3: veligrotug (a conventional IgG1) and VRDN-003 (a half-life-extended, next-generation construct). Both are being evaluated for TED, a condition affecting roughly 0.25 % of the U.S. adult population and representing a $1.5 bn addressable market according to recent market-research estimates. In parallel, Viridian is advancing anti-neonatal Fc receptor (FcRn) candidates (VRDN-006, VRDN-008) aimed at broader autoimmune indications, though these remain pre-clinical.

As of the latest 10-Q (Q2 2024), the company reported cash and equivalents of $85 million and a monthly burn rate of approximately $6 million, giving it ~14 months of runway absent additional financing. The biotech sector’s capital-raising environment has tightened since 2022, making cash-runway a critical risk factor for early-stage firms. Moreover, the success of Phase 3 trials in TED would place Viridian in a niche with limited competition-current FDA-approved therapies (e.g., teprotumumab) are priced above $30,000 per course, suggesting strong pricing power if efficacy is demonstrated.

For a deeper, data-driven assessment of VRDN’s risk-adjusted upside, you may find the analytics on ValueRay useful-its platform aggregates trial-stage metrics and cash-flow forecasts that can help you quantify the potential impact of a Phase 3 readout.

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-302.0m TTM) > 0 and > 6% of Revenue (6% = 4.25m TTM)

FCFTA -0.57 (>2.0%) and ΔFCFTA -30.97pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 736.3% (prev 240.4k%; Δ -239.7kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.56 (>3.0%) and CFO -326.0m <= Net Income -302.0m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 11.28 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (81.8m) change vs 12m ago 23.13% (target <= -2.0% for YES)

Gross Margin 99.83% (prev -2048 %; Δ 2148 pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 10.49% (prev 0.04%; Δ 10.46pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -118.9 (EBITDA TTM -299.0m / Interest Expense TTM 2.52m) >= 6 (WARN >= 3)

Altman Z'' -21.17

(A) 0.90 = (Total Current Assets 571.9m - Total Current Liabilities 50.7m) / Total Assets 577.1m

(B) -2.11 = Retained Earnings (Balance) -1.22b / Total Assets 577.1m

warn (B) unusual magnitude: -2.11 — check mapping/units

(D) -16.41 = Book Value of Equity -1.22b / Total Liabilities 74.2m

Total Rating: -21.17 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 46.85

1. Piotroski 1.0pt

2. FCF Yield -12.80%

3. FCF Margin data missing

4. Debt/Equity 0.05

5. Debt/Ebitda 0.49

7. RoE -52.65%

8. Rev. Trend 12.25%

9. EPS Trend 52.23%

What is the price of VRDN shares?

As of December 23, 2025, the stock is trading at USD 32.47 with a total of 2,240,528 shares traded.
Over the past week, the price has changed by -1.70%, over one month by +1.37%, over three months by +66.09% and over the past year by +65.07%.

Is VRDN a buy, sell or hold?

Viridian Therapeutics has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy VRDN.

Strong Buy: 9
Buy: 5
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the VRDN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	40.2	23.8%
Analysts Target Price	40.2	23.8%
ValueRay Target Price	35	7.9%

VRDN Fundamental Data Overview December 20, 2025

Market Cap USD = 3.02b (3.02b USD * 1.0 USD.USD)
P/S = 42.605
P/B = 9.6054
Beta = 0.914
Revenue TTM = 70.8m USD
EBIT TTM = -299.5m USD
EBITDA TTM = -299.0m USD
Long Term Debt = 20.9m USD (from longTermDebt, last quarter)
Short Term Debt = 730.0k USD (from shortTermDebt, last quarter)
Debt = 23.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -145.8m USD (from netDebt column, last quarter)
Enterprise Value = 2.55b USD (3.02b + Debt 23.8m - CCE 490.9m)
Interest Coverage Ratio = -118.9 (Ebit TTM -299.5m / Interest Expense TTM 2.52m)
FCF Yield = -12.80% (FCF TTM -326.3m / Enterprise Value 2.55b)
FCF Margin = -461.0% (FCF TTM -326.3m / Revenue TTM 70.8m)
Net Margin = -426.6% (Net Income TTM -302.0m / Revenue TTM 70.8m)
Gross Margin = 99.83% ((Revenue TTM 70.8m - Cost of Revenue TTM 123.0k) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 100.0%)
Tobins Q-Ratio = 4.42 (Enterprise Value 2.55b / Total Assets 577.1m)
Interest Expense / Debt = 2.35% (Interest Expense 560.0k / Debt 23.8m)
Taxrate = 100.0% (out of range, set to none) (-269.9m / -269.9m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 11.28 (Total Current Assets 571.9m / Total Current Liabilities 50.7m)
Debt / Equity = 0.05 (Debt 23.8m / totalStockholderEquity, last quarter 503.0m)
Debt / EBITDA = 0.49 (negative EBITDA) (Net Debt -145.8m / EBITDA -299.0m)
Debt / FCF = 0.45 (negative FCF - burning cash) (Net Debt -145.8m / FCF TTM -326.3m)
Total Stockholder Equity = 573.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -52.32% (Net Income -302.0m / Total Assets 577.1m)
RoE = -52.65% (Net Income TTM -302.0m / Total Stockholder Equity 573.6m)
RoCE = -50.37% (EBIT -299.5m / Capital Employed (Equity 573.6m + L.T.Debt 20.9m))
RoIC = -842.6% (out of range, set to none) (EBIT -299.5m / (Assets 577.1m - Curr.Liab 50.7m - Cash 490.9m))
WACC = 9.28% (E(3.02b)/V(3.04b) * Re(9.35%) + (debt cost/tax rate unavailable))
Discount Rate = 9.35% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 28.30%
Fair Price DCF = unknown (Cash Flow -326.3m)
EPS Correlation: 52.23 | EPS CAGR: 39.53% | SUE: 2.68 | # QB: 1
Revenue Correlation: 12.25 | Revenue CAGR: 369.4% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-1.13 | Chg30d=-0.030 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=-3.48 | Chg30d=-0.085 | Revisions Net=+1 | Growth EPS=+0.6% | Growth Revenue=+4.5%

Additional Sources for VRDN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle